Parkinson's Disease Therapeutic Market Current Scenario with Future Aspect Analysis

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Parkinson's Disease Therapeutic Market is valued at US$ 4.22 Bn in 2023, and it is expected to reach US$ 6.51 Bn by 2031, with a CAGR of 5.7% during the forecast period of 2024-2031.

Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2587

Parkinson's disease (PD) is a progressive and debilitating neurological disorder that primarily affects motor function. Current therapeutic approaches focus on symptom management and enhancing patients' quality of life. The market for Parkinson's disease treatment is experiencing growth due to heightened awareness and earlier diagnosis of the condition. Advances in diagnostic methodologies-such as high-resolution imaging and the identification of reliable biomarkers-are facilitating timely intervention, thereby improving treatment outcomes.

Furthermore, increased investments in research and development by pharmaceutical companies and government agencies are driving innovation in therapeutic options. Strategic collaborations between biotechnology firms and academic institutions are accelerating drug discovery and the development of novel therapies. Additionally, the integration of digital health solutions, such as wearable monitoring devices and telemedicine platforms, is enhancing disease management and supporting patient adherence to treatment protocols, contributing to sustained market expansion.

List of Prominent Players in the Parkinson's Disease Therapeutic Market:
• Teva Pharmaceutical Industries Ltd.,
• Novartis AG
• GlaxoSmithKline Plc.
• AbbVie Inc.
• Merck & Co. Inc.,
• Zydus Cadila
• Dr. Reddy's
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Boehringer Ingelheim International GmbH
• Denali Therapeutics Inc.
• Biogen Inc.
• Prevail Therapeutics
• Eli Lilly and Company
• Voyager Therapeutics.
• Intas Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Amneal Pharmaceuticals
• Aurobindo Pharma Limited
• Accord Healthcare Ltd.

Market Dynamics:
Drivers-
The global rise in the prevalence of Parkinson's disease (PD) is a key factor propelling the growth of the therapeutic market. Enhanced awareness and the advancement of diagnostic tools have led to earlier detection of PD, thereby increasing the demand for effective treatment options. The availability of diverse therapeutic approaches, tailored to various stages and severities of the disease, is further supporting improved patient outcomes and expanding the market base. In addition, the integration of artificial intelligence (AI) and machine learning technologies into drug discovery and development is transforming the industry.

Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2587

Challenges:
A key challenge facing the Parkinson's disease therapeutics market is the declining rate of regulatory approvals for new drugs. This trend restricts the introduction of innovative therapies, limiting treatment options for patients and healthcare professionals.

Regional Trends:
North America leads the global Parkinson's disease therapeutics market, supported by a high prevalence of the disease, particularly among the ageing population. The United States, in particular, benefits from a robust healthcare infrastructure and widespread awareness initiatives, contributing to significant market growth.

Recent Developments:
• In March 2024, Sanofi and Cipla have formed an exclusive collaboration to distribute and promote Sanofi India's Central Nervous System (CNS) product range in India. Under this collaboration, Cipla will assume the responsibility of distributing Sanofi India's six CNS brands, which includes Frisium®, a prominent brand in the anti-epileptic drug field.
• In Oct 2022, Biogen and Denali Therapeutics commenced the Phase 3 LIGHTHOUSE Study in Parkinson's Disease linked to LRRK2 Pathogenic Mutations. The main objective of the LIGHTHOUSE trial was to measure the duration until proven deterioration, evaluated using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), during the treatment term of up to 180 weeks.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/2587

Segmentation of Parkinson's Disease Therapeutic Market-
By Drugs
• Carbidopa-levodopa
• Dopamine agonists
• Mao-b inhibitors
• COMT inhibitors
• Anticholinergics
• Others
By Distribution Channel-
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
By Brand
• Branded
• Generics
By Route of Administration
• Oral,
• Injectable,
• Intestinal Infusion,
• Subcutaneous
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Get More Information: @
https://www.insightaceanalytic.com/report/parkinsons-disease-therapeutic-market/2587

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

This release was published on openPR.